| Citation: |
DONG Kaixuan, CHEN Danni, ZHENG Ya, WANG Yuping, GUO Qinghong. The Role of CEACAM1 in Metabolic Dysfunction-associated Steatotic Liver Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1117-1123. DOI: 10.12290/xhyxzz.2024-0035
|
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a transmembrane protein of the immunoglobulin superfamily, is involved in mediating cell adhesion, tissue metastasis, control of immune response, and metabolic homeostasis. Studies have shown that CEACAM1 protects the liver by promoting insulin clearance and preventing fat deposition. The down-regulation of the CEACAM1 expression level leads to a vicious cycle of insulin resistance and aggravates metabolic disorders. As CEACAM1 is critical in controlling metabolic dysfunction-associated steatotic liver disease (MASLD), stimulating its pathway or regulating its expression level might be a potential new therapeutic approach for MASLD. In this paper, therefore, we summarize the research progress of CEACAM1 in MASLD.
| [1] |
Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347. DOI: 10.1097/HEP.0000000000000004
|
| [2] |
Loomba R, Wong V W S. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease[J]. Aliment Pharmacol Ther, 2024, 59(2): 150-156. DOI: 10.1111/apt.17846
|
| [3] |
Harrison S A, Dubourg J, Knott M, et al. Hyperinsuline-mia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease[J/OL]. Hepatology, 2023. doi: 10.1097/hep.0000000000000710.
|
| [4] |
Yanai H, Adachi H, Hakoshima M, et al. Metabolic- dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments[J]. Int J Mol Sci, 2023, 24(20): 15473. DOI: 10.3390/ijms242015473
|
| [5] |
Kube-Golovin I, Lyndin M, Wiesehöfer M, et al. CEACAM expression in an in-vitro prostatitis model[J]. Front Immunol, 2023, 14: 1236343. DOI: 10.3389/fimmu.2023.1236343
|
| [6] |
Thomas J, Klebanov A, John S, et al. CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens[J]. Genes Cancer, 2023, 14: 12-29. DOI: 10.18632/genesandcancer.230
|
| [7] |
Lee W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes[J]. Diagn Pathol, 2011, 6(1): 40. DOI: 10.1186/1746-1596-6-40
|
| [8] |
Heinrich G, Ghadieh H E, Ghanem S S, et al. Loss of hepatic CEACAM1: a unifying mechanism linking insulin resistance to obesity and non-alcoholic fatty liver disease[J]. Front Endocrinol (Lausanne), 2017, 8: 8.
|
| [9] |
Lee W H, Najjar S M, Kahn C R, et al. Hepatic insulin receptor: new views on the mechanisms of liver disease[J]. Metabolism, 2023, 145: 155607. DOI: 10.1016/j.metabol.2023.155607
|
| [10] |
Russo L, Muturi H T, Ghadieh H E, et al. Liver-specific rescuing of CEACAM1 reverses endothelial and cardi-ovascular abnormalities in male mice with null deletion of Ceacam1 gene[J]. Mol Metab, 2018, 9: 98-113. DOI: 10.1016/j.molmet.2018.01.009
|
| [11] |
Hajihassan Z, Mohammadpour Saray M, Yaseri A. Engineering a CEACAM1 variant with the increased binding affinity to TIM-3 receptor[J]. Iran Biomed J, 2023, 27(4): 191-198.
|
| [12] |
Dery K J, Kojima H, Kageyama S, et al. Alternative splicing of CEACAM1 by hypoxia-inducible factor-1α enhances tolerance to hepatic ischemia in mice and humans[J]. Sci Transl Med, 2023, 15(707): eadf2059. DOI: 10.1126/scitranslmed.adf2059
|
| [13] |
刘传, 李丽娟, 王嵘, 等. CEACAM5在肺腺癌中的表达及临床意义[J]. 临床肺科杂志, 2022, 27(2): 256-261. DOI: 10.3969/j.issn.1009-6663.2022.02.020
Liu C, Li L J, Wang R, et al. Expression and clinical significance of CEACAM5 in lung adenocarcinoma[J]. J Clin Pulm Med, 2022, 27(2): 256-261. DOI: 10.3969/j.issn.1009-6663.2022.02.020
|
| [14] |
马凯, 王鸽, 孙建兵, 等. HopQ与人CEACAM1相互作用的研究进展[J]. 医学综述, 2019, 25(17): 3433-3437. DOI: 10.3969/j.issn.1006-2084.2019.17.020
Ma K, Wang G, Sun J B, et al. Research progress of HopQ interaction with human CEACAM1[J]. Med Recapitulate, 2019, 25(17): 3433-3437. DOI: 10.3969/j.issn.1006-2084.2019.17.020
|
| [15] |
Fan Y J, Yan Z P, Li T T, et al. Primordial drivers of diabetes heart disease: comprehensive insights into insulin resistance[J]. Diabetes Metab J, 2024, 48(1): 19-36. DOI: 10.4093/dmj.2023.0110
|
| [16] |
Schwärzler J, Grabherr F, Grander C, et al. The pathophysiology of MASLD: an immunometabolic perspective[J]. Expert Rev Clin Immunol, 2024, 20(4): 375-386. DOI: 10.1080/1744666X.2023.2294046
|
| [17] |
Vesković M, Šutulović N, Hrnčić D, et al. The interconnection between hepatic insulin resistance and metabolic dysfunction-associated steatotic liver disease-the transition from an adipocentric to liver-centric approach[J]. Curr Issues Mol Biol, 2023, 45(11): 9084-9102. DOI: 10.3390/cimb45110570
|
| [18] |
Margolis R N, Taylor S I, Seminara D, et al. Identification of pp120, an endogenous substrate for the hepatocyte insulin receptor tyrosine kinase, as an integral membrane glycoprotein of the bile canalicular domain[J]. Proc Natl Acad Sci U S A, 1988, 85(19): 7256-7259. DOI: 10.1073/pnas.85.19.7256
|
| [19] |
Najjar S M. Regulation of insulin action by CEACAM1[J]. Trends Endocrinol Metab, 2002, 13(6): 240-245. DOI: 10.1016/S1043-2760(02)00608-2
|
| [20] |
Choice C V, Howard M J, Poy M N, et al. Insulin stimulates pp120 endocytosis in cells co-expressing insulin receptors[J]. J Biol Chem, 1998, 273(35): 22194-22200. DOI: 10.1074/jbc.273.35.22194
|
| [21] |
Bergman R N, Kabir M, Ader M. The physiology of insulin clearance[J]. Int J Mol Sci, 2022, 23(3): 1826. DOI: 10.3390/ijms23031826
|
| [22] |
Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2014, 59(6): 2178-2187. DOI: 10.1002/hep.26988
|
| [23] |
De Vries M, El-Morabit F, Van Erpecum K J, et al. Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes[J]. Eur J Intern Med, 2022, 100: 77-82. DOI: 10.1016/j.ejim.2022.03.025
|
| [24] |
De Vries M, Westerink J, Kaasjager K H A H, et al. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2020, 105(12): 3842-3853. DOI: 10.1210/clinem/dgaa575
|
| [25] |
Poy M N, Ruch R J, Fernstrom M A, et al. Shc and CEACAM1 interact to regulate the mitogenic action of insulin[J]. J Biol Chem, 2002, 277(2): 1076-1084. DOI: 10.1074/jbc.M108415200
|
| [26] |
Yousef A A, Behiry E G, Allah W M A, et al. IRS-1 genetic polymorphism (r.2963G > A) in type 2 diabetes mellitus patients associated with insulin resistance[J]. Appl Clin Genet, 2018, 11: 99-106. DOI: 10.2147/TACG.S171096
|
| [27] |
Poy M N, Yang Y, Rezaei K, et al. CEACAM1 regulates insulin clearance in liver[J]. Nat Genet, 2002, 30(3): 270-276. DOI: 10.1038/ng840
|
| [28] |
Nagaishi T, Pao L, Lin S H, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms[J]. Immunity, 2006, 25(5): 769-781. DOI: 10.1016/j.immuni.2006.08.026
|
| [29] |
Mahmoud A M, Szczurek M R, Blackburn B K, et al. Hyperinsulinemia augments endothelin-1 protein expression and impairs vasodilation of human skeletal muscle arterioles[J]. Physiol Rep, 2016, 4(16): e12895. DOI: 10.14814/phy2.12895
|
| [30] |
Abu Helal R, Muturi H T, Lee A D, et al. Aortic fibrosis in insulin-sensitive mice with endothelial cell-specific deletion of Ceacam1 gene[J]. Int J Mol Sci, 2022, 23(8): 4335. DOI: 10.3390/ijms23084335
|
| [31] |
Muturi H T, Ghadieh H E, Abdolahipour R, et al. Loss of CEACAM1 in endothelial cells causes hepatic fibrosis[J]. Metabolism, 2023, 144: 155562. DOI: 10.1016/j.metabol.2023.155562
|
| [32] |
Helal R A, Russo L, Ghadieh H E, et al. Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1[J]. Metabolism, 2021, 121: 154801. DOI: 10.1016/j.metabol.2021.154801
|
| [33] |
Yan M L, Li H, Xu S Y, et al. Targeting endothelial necroptosis disrupts profibrotic endothelial-hepatic stellate cells crosstalk to alleviate liver fibrosis in nonalcoholic steatohepatitis[J]. Int J Mol Sci, 2023, 24(14): 11313. DOI: 10.3390/ijms241411313
|
| [34] |
Laurenti M C, Dalla Man C, Varghese R T, et al. Insulin pulse characteristics and insulin action in non-diabetic humans[J]. J Clin Endocrinol Metab, 2021, 106(6): 1702-1709. DOI: 10.1210/clinem/dgab100
|
| [35] |
DeBose-Boyd R A, Ye J. SREBPs in lipid metabolism, insulin signaling, and beyond[J]. Trends Biochem Sci, 2018, 43(5): 358-368. DOI: 10.1016/j.tibs.2018.01.005
|
| [36] |
Matveyenko A V, Liuwantara D, Gurlo T, et al. Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling[J]. Diabetes, 2012, 61(9): 2269-2279. DOI: 10.2337/db11-1462
|
| [37] |
Ramakrishnan S K, Khuder S S, Al-Share Q Y, et al. PPARα (peroxisome proliferator-activated receptor α) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting-refeeding transition[J]. J Biol Chem, 2016, 291(15): 8121-8129. DOI: 10.1074/jbc.M116.714014
|
| [38] |
Najjar S M, Caprio S, Gastaldelli A. Insulin clearance in health and disease[J]. Annu Rev Physiol, 2023, 85: 363-381. DOI: 10.1146/annurev-physiol-031622-043133
|
| [39] |
Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD-more than inflammation[J]. Nat Rev Endocrinol, 2022, 18(8): 461-472. DOI: 10.1038/s41574-022-00675-6
|
| [40] |
Ruck L, Wiegand S, Kühnen P. Relevance and consequence of chronic inflammation for obesity development[J]. Mol Cell Pediatr, 2023, 10(1): 16. DOI: 10.1186/s40348-023-00170-6
|
| [41] |
Hayakawa F, Soga K, Fujino J, et al. Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium[J]. Biochem Biophys Rep, 2023, 36: 101575.
|
| [42] |
Kakino S, Ohki T, Nakayama H, et al. Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model[J]. Horm Metab Res, 2018, 50(1): 80-87. DOI: 10.1055/s-0043-118666
|
| [43] |
DeAngelis A M, Heinrich G, Dai T, et al. Carcinoembry-onic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism[J]. Diabetes, 2008, 57(9): 2296-2303. DOI: 10.2337/db08-0379
|
| [44] |
Park S Y, Cho Y R, Kim H J, et al. Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1[J]. Am J Physiol Endocrinol Metab, 2006, 291(3): E517-E524.
|
| [45] |
Al-Share Q Y, DeAngelis A M, Lester S G, et al. Forced hepatic overexpression of CEACAM1 curtails Diet-Induced insulin resistance[J]. Diabetes, 2015, 64(8): 2780-2790. DOI: 10.2337/db14-1772
|
| [46] |
Wang Z Y, Sun T T, Yu J J, et al. FGF21: a sharp weapon in the process of exercise to improve NAFLD[J]. Front Biosci (Landmark Ed), 2023, 28(12): 351. DOI: 10.31083/j.fbl2812351
|
| [47] |
Bakker L E H, Van Schinkel L D, Guigas B, et al. A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young South Asian men but not in Caucasian men[J]. Diabetes, 2014, 63(1): 248-258. DOI: 10.2337/db13-0696
|
| [48] |
Pezzino S, Sofia M, Mazzone C, et al. Exploring public interest in gut microbiome dysbiosis, NAFLD, and probiotics using Google Trends[J]. Sci Rep, 2024, 14(1): 799. DOI: 10.1038/s41598-023-50190-5
|
| [49] |
Park D J, Sung P S, Kim J H, et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1[J]. J Immunother Cancer, 2020, 8(1): e000301. DOI: 10.1136/jitc-2019-000301
|
| [50] |
Khairnar V, Duhan V, Patil A M, et al. CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection[J]. Nat Commun, 2018, 9(1): 2561. DOI: 10.1038/s41467-018-04832-2
|
| [51] |
Adams D H, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease[J]. Nat Rev Immunol, 2006, 6(3): 244-251. DOI: 10.1038/nri1784
|
| [52] |
He R H, Zhao S B, Cui M Y, et al. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations[J]. Front Immunol, 2023, 14: 1234535. DOI: 10.3389/fimmu.2023.1234535
|
| [53] |
Horst A K, Wegscheid C, Schaefers C, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 controls IL-2-dependent regulatory T-cell induction in immune-mediated hepatitis in mice[J]. Hepatology, 2018, 68(1): 200-214. DOI: 10.1002/hep.29812
|
| [54] |
Vallianou N, Christodoulatos G S, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives[J]. Biomolecules, 2021, 12(1): 56. DOI: 10.3390/biom12010056
|
| [55] |
Chen L F, Chen Z G, Baker K, et al. The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction[J]. Immunity, 2012, 37(5): 930-946. DOI: 10.1016/j.immuni.2012.07.016
|
| [56] |
Gruzdev S K, Podoprigora I V, Gizinger O A. Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets[J]. Arch Microbiol, 2024, 206(2): 62. DOI: 10.1007/s00203-023-03752-0
|
| [57] |
Najjar S M, Perdomo G. Hepatic insulin clearance: mechanism and physiology[J]. Physiology (Bethesda), 2019, 34(3): 198-215.
|
| [58] |
Salehi M, Aulinger B, Prigeon R L, et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes[J]. Diabetes, 2010, 59(6): 1330-1337. DOI: 10.2337/db09-1253
|
| [59] |
Ghadieh H E, Muturi H T, Russo L, et al. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis[J]. Hepatol Commun, 2018, 2(1): 35-47. DOI: 10.1002/hep4.1117
|
| [60] |
Ghadieh H E, Muturi H T, Najjar S M. Exenatide prevents diet-induced hepatocellular injury in a CEACAM1-dependent mechanism[J]. J Diabetes Treat, 2017, 2017(4): JDBT-133.
|
| [1] | YU Jiawen, LIU Hongju, XU Yingying, BAO Yanping, SHI Jie, LIU Zhimin, ZHANG Yuelun, NING Xiaohong, HUANG Yuguang. Cognition of Palliative Care and Experience of Palliative Sedation in Chinese Anesthesiologists: A National Cross-sectional Survey[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 77-83. DOI: 10.12290/xhyxzz.2023-0158 |
| [2] | WANG Bo, JIANG Wei, LUO Yuping. Talking About Palliative Care Recipients From the Perspective of Promoting Living Wills[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(1): 42-44. DOI: 10.12290/xhyxzz.2023-0617 |
| [3] | CHEN Long, REN Minghui. Review and Perfection of Living Will System[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0161 |
| [4] | LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271 |
| [5] | CAI Siyu, GUO Qiaohong, NING Xiaohong, LU Guijun, GUO Yanru, LIU Yin, QIN Xinyan, WANG Xianjing, YAN Tianyi, WANG Ruixin, ZHOU Xuan, PENG Xiaoxia, Pediatric Palliative Care Subspecialty Group of the Pediatrics Society of the Chinese Medical Association. Cross-cultural Adaptation of the Document of Advance Care Planning for Chinese Adolescents and Young Adults: Voicing My CHOiCES[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(1): 96-103. DOI: 10.12290/xhyxzz.2021-0162 |
| [8] | Ming-sheng MA, Xü-de ZHANG, Min WEI, Shi-min ZHAO, Zheng-qing QIU. Efficacy of Low Dose Corticosteroid Therapy in Duchenne Muscular Dystrophy[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 384-388. DOI: 10.3969/j.issn.1674-9081.2014.04.006 |
| [9] | Jie LIU, Yue-ping ZENG, Chun-xia HE, Qin LONG, Hong-zhong JIN, Qiu-ning SUN. Corticosteroids plus Intravenous Immunoglobulin in the Treatment of 7 Cases with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 381-385. DOI: 10.3969/j.issn.1674-9081.2012.04.004 |
| [10] | Shuai TANG, Jie YI, Yu-guang HUANG. Cardiovascular Responses of Intubation with Shikani Seeing Optical Stylet and Macintosh Laryngoscope[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(3): 314-317. DOI: 10.3969/j.issn.1674-9081.2012.03.015 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: